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1. Introduction 
Patients with rheumatoid arthritis (RA) or other inflammatory arthropathies often require 
orthopedic surgery, and the management of their medical treatments during the 
perioperative period is an important issue. The two main concerns during this period are 
the risk of infection and wound healing complications. 
These patients receive multidisciplinary care from orthopedic surgeons, rehabilitators and 
rheumatologists (1). Before orthopedic surgery, the activity of the arthropathy and the non-
biological and biological therapies of patients must be taken into consideration for an 
optimal outcome with no infectious or wound-healing complications. Good clinical and 
biological control of the disease must be obtained before the surgery, and effective 
coordination between surgeon and rheumatologist is essential (2). 
The management of non-biological (immunosuppressive or immunomodulatory) and 
biological therapies in orthopedic surgery patients remains controversial. This chapter 
focuses on disease-modifying anti-rheumatic drugs (DMARDs) and biological therapies (see 
table 1). Although corticosteroids are immunosuppressants, protocols for their replacement 
or supplementation are well established in the literature and are not addressed here (3). 
DMARDs and especially biological therapies are the subject of multiple consultations 
between rheumatologists and orthopedists or anesthetists before surgery. The objective of 
this chapter is to discuss current protocols for the application of these treatments before and 
after orthopedic surgery, based on the best available scientific evidence or, in its absence, on 
accepted recommendations. 
2. Disease-modifying anti-rheumatic drugs (DMARDS) 
2.1 Methotrexate (MTX) 
Until five years ago, there was a tendency to withdraw MTX at around two weeks before 
surgery, based on reports in various retrospective studies of a higher risk of postoperative 
complications, especially infections (4). However, a well-designed prospective study by 
Grennan et al. (5) in 388 patients concluded that the continuation of MTX treatment did not  
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MODIFYING DRUGS (DMARDS) BIOLOGICAL THERAPIES 
- METHOTREXATE 
- ANTI-MALARIALS 
- LEFLUNOMIDE 
- SULFASALAZINE 
- CYCLOSPORINE A 
- GOLD COMPOUNDS 
- AZATHIOPRINE 
- INFLIXIMAB 
- ETANERCEPT 
- ADALIMUMAB (D2E7) 
- CERTOLIZUMAB 
- GOLIMUMAB 
- ANAKINRA (rHuIL-1Ra) 
- RITUXIMAB 
- ABATACEPT 
- TOCILIZUMAB 
Table 1. Modifying drugs and biological therapies used in rheumatoid arthritis 
increase infection risk or delay wound-healing. Furthermore, patients who had continued 
with their MTX treatment had fewer postoperative inflammatory outbreaks in comparison 
to those who had not, and the latter showed a non-significant tendency to a higher 
frequency of post-surgical complications. Nevertheless, although a rare complication, MTX-
associated lymphoproliferative disorders consist of a heterogeneous group of lymphoid 
proliferations or lymphomas (mainly diffuse large B-cell lymphoma or Hodgkin lymphoma) 
that develop in patients with autoimmune diseases after prolonged MTX treatment. These 
lymphoproliferative disorders are often associated with Epstein-Barr virus infection and 
occasionally regress after the withdrawal of MTX therapy (6).  
2.2 Anti-malarials 
The anti-malarials used in RA patients are chloroquine and especially hydroxychloroquine, 
due to its lower ocular toxicity. After their prolonged administration, anti-malarials 
accumulate in multiple tissues (kidney, spleen, liver, etc). For this reason, despite the 
absence of well-designed studies, it does not appear appropriate or meaningful to interrupt 
their administration immediately before surgery. Nevertheless, it should be borne in mind 
that anti-malarials inhibit platelet aggregation and adhesion (7) and may therefore increase 
the risk of bleeding.  
2.3 Leflunomide (LFN), sulfasalazine, and gold compounds 
LFN inhibits pyrimidine synthesis and offers a similar effectiveness to that of MTX but with 
a greater selectivity, reversibly inhibiting the proliferation of activated autoimmune 
lymphocytes. Although a low risk of infection was reported in various clinical trials, there 
appear to be no studies that evaluate this risk or the effects on postoperative wound-healing. 
However, because LFN can potentiate anticoagulation, the dosage should be adjusted in 
patients receiving this drug as prophylaxis against deep vein thrombosis (7). With respect to 
sulfasalazine and gold compounds, no good scientific evidence is available on their 
perioperative administration. In general, however, the perioperative suspension of their 
administration is not recommended (8). 
2.4 Cyclosporine A and azathioprine 
Although there have been no well-designed studies, various publications (7,10) have 
reported that infections are more frequent after orthopedic surgery in patients receiving 
azathioprine or cyclosporine A. For this reason, it is recommended to withdraw these drugs 
one week before and reintroduce them two weeks after this surgery.  
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3. Biological therapies 
Unlike the treatments reported above, biological therapies are designed to specifically block 
molecules with important pathophysiological roles in AR and other inflammatory 
arthropies. These molecules include various proinflammatory cytokines, such as tumor 
necrosis factor-alpha (TNF-a), interleukin 6 (IL-6), and interleukin 1 (IL-1), which are 
responsible for chronic synovitis, bone destruction, and systemic manifestations. Other 
biological drugs have been developed against cells that participate in the pathogenesis of 
RA, such as rituximab, directed against CD20 B cells, and abatacept, which prevents 
activation of T lymphocytes and has shown effectiveness in controlling the disease. 
Biological drugs are proteins (monoclonal antibodies or soluble receptors against cytokines, 
receptors, or cell surface molecules) obtained by biotechnology that block the above-
mentioned cytokines or modulate B or T cells in a specific manner. The following are 
currently available: 
- Drugs directed against TNF-a, either monoclonal antibodies (infliximab, adalimumab, 
certolizumab, or golimumab) or soluble receptors (etanercept). Their administration 
form and dosage differ according to the pharmacokinetics of these products. 
- Abatacept is a fusion protein that blocks the T lymphocyte co-stimulation signal 
mediated by CD28; it is administered intravenously every 4 weeks. 
- Tocilizumab is a humanized monoclonal antibody against IL-6 receptor; it is 
administered intravenously at an initial dose of 4 mg/kg (USA) or 8 mg/kg (Europe, 
Japan) every 4 weeks.  
- Rituximab is a chimeric monoclonal antibody against the CD20 marker for B 
lymphocytes; it is administered intravenously at a dose of 500 or 1000 mg on days 0 and 
15 and repeated every 6-12 months according to the disease activity. 
- Anakhinra is a recombinant human antagonist of IL-1 receptor; it is administered 
subcutaneously every day. 
These drugs block cytokines or modulate cells involved in the cell immune response to 
infections. Hence, in theory, they should be withdrawn before surgery, despite the absence 
of clinical studies to support this decision. No clinical trial has addressed complications after 
orthopedic surgery in RA patients receiving biological treatments, but there have been some 
retrospective studies. Bibbo et al. (11) investigated the influence of infliximab and etanercept 
in orthopedic surgery and concluded that they could be administered safely in the 
perioperative period without increasing the risk of infectious or wound-healing 
complications. However, the pathologic study of the wounds is not reported, and the 
authors do not describe how they assessed wound-healing delay or bone-healing 
complications, two key variables in their study. A more recent retrospective study on 
clinical factors related to infliximab-treated RA patients undergoing orthopedic surgery (12) 
concludes that infliximab does not increase the risk of surgical or infectious complications at 
one year post-surgery. We did not observe any wound healing complications after hand 
surgery in fourteen rheumatoid patients treated with etanercept or infliximab (Fig. 1 and 2). 
Experimental results of TNF-a administration in murine models of wound-healing 
complications have not been consistent. Although TNF-a inhibition could theoretically have 
a negative impact on wound-healing (13), studies by our group and other authors suggest 
that it may improve collagenization of the wound (14), supporting its continuation during 
the perioperative period (Fig 3 and 4). 
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Fig. 1. Metacarpophalangeal deformity and arthritis in right hand of woman with 
rheumatoid arthritis and under treatment with etanercept. Surgical wound for implantation 
of metacarpophalangeal prosthesis. Treatment was not suspended during the perioperative 
period. Surgical wound healing was excellent. 
No data are available on the effect of rituximab on surgical complications in RA patients. Its 
administration produces a prolonged (6 months–1 year) depletion of CD-19B lymphocytes 
and may therefore increase the risk of perioperative infection. Its effects on wound-healing 
are less clear. It therefore appears prudent to suspend treatment and delay surgery until the 
CD-19 lymphocyte B count of the patient is normalized (15). Nevertheless, experience with 
the administration of rituximab to lymphoma patients undergoing surgery suggests that it 
can be continued when surgery is essential and that its administration should not be a 
contraindication for surgery. 
Tocilizumab blocks IL-6, inducing hepatic synthesis of C-reactive protein (CRP), which may 
mask signs and symptoms of post-surgical infectious complications, such as fever or 
elevated CRP (16, 17). The effects of IL-6 inhibition on wound-healing, by interfering with 
the initial inflammatory phase of the surgical wound, are not known.  
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Fig. 2. Ulnar deformity and metacarpophalangeal arthritis in right hand of man with 
rheumatoid arthritis under treatment with infliximab and that underwent 
metacarpophalangeal prosthesis. Treatment was not suspended during the perioperative 
period. Wound-healing was satisfactory, with no complications.  
 
 
Fig. 3. Skin wound-healing during a 3-week period in etanercept-treated. DAB1J mice with 
collagen-induced arthritis  
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Fig. 4. Severe osteoarticular lesions in DAB1J mice with collagen-induced arthritis at day 15 
(upper-left image). Absence of osteorticular lesions in etanercept-treated mice (upper-right 
image). Skin wound-healing in DAB1J mice with collagen-induced arthritis at day 15. Note 
complete re-epithelization and skin appendages recovery in control (lower left image) and 
etanercept-treated (lower right image) mice [original magnification 4x, Masson Trichrome 
stain]. 
We could find no study on the effect of abatacept on surgical complications or wound 
healing. However, no associated postoperative complications were described in case reports 
on infections in patients who underwent surgery while receiving this drug (18). 
Given the above data, and until new scientific evidence becomes available, it appears 
sensible to suspend these treatments before surgery, determining the pre-surgical interval 
according to the drug’s half-life, only reintroducing them when the wound has healed with 
no complications. We propose the following recommendations (summarized in Table 2) for 
each drug. 
- Infliximab: suspend treatment 6 weeks before surgery. 
- Adalimumab: suspend treatment 2 weeks before surgery. 
- Golimumab/Certolizumab: suspend treatment 4 weeks before surgery. 
- Etanercept: suspend treatment 1 week before surgery.  
- Anakinra: suspend treatment 24-48 hours before surgery. 
- Rituximab: suspend treatment and delay surgery until serum levels of CD-19 B 
lymphocytes normalize (usually 3-6 months after last dose). Nevertheless, if urgent 
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surgery is required or cannot be delayed due to the patient’s condition, surgery can be 
performed without normalization of these serum levels. 
- Tocilizumab: suspend treatment 4 weeks before surgery but take into account that 
patients with infectious complications may not present with elevated CRP levels or 
fever. 
- Abatacept: suspend treatment 4 weeks before surgery. 
 
BIOLOGICAL THERAPY  TIMING OF SUSPENSION BEFORE SURGERY 
INFLIXIMAB 6 WEEKS 
ETANERCEPT 1 WEEK 
ADALIMUMAB (D2E7) 2 WEEKS 
CERTOLIZUMAB 4 WEEKS 
GOLIMUMAB 4 WEEKS 
ANAKINRA (rHuIL-1Ra) 24-48 HOURS 
RITUXIMAB 
AFTER NORMALIZATION OF SERUM LEVELS OF 
CD-19 B LYMPHOCYTES (3-6 MONTHS) 
ABATACEPT 4 WEEKS 
TOCILIZUMAB 4 WEEKS 
Table 2. Biological therapies and recommended timing of their suspension before surgery 
Future therapies 
Considerable clinical and experimental evidence suggests that various endogenous 
neuropeptides play a major role in educating our immune system to be self-tolerant. The 
fact that neuropeptides regulate various layers involved in the maintenance of tolerance, 
including regulation of the balance between pro-inflammatory and anti-inflammatory 
responses and between self-reactive Th1/Th17 cells and regulatory T cells, makes them 
attractive candidates for the development of novel therapies to treat autoimmune disorders 
such as RA. Vasoactive intestinal peptide is the paradigmatic immunomodulatory 
neuropeptide, but other neuropeptides possess similar properties, including melanocyte-
stimulating hormone, urocortin, adrenomedullin, neuropeptide Y, cortistatin, and ghrelin 
(19). All have demonstrated marked beneficial effects in animal models of collagen-induced 
arthritis without affecting wound healing (20-23).  
4. Conclusions 
In the majority of cases, there are no well-designed studies to support clear 
recommendations on the perioperative management of patients with inflammatories 
arthropies receiving anti-rheumatic treatment, especially the new biological therapies. 
Available evidence suggests that methotrexate, anti-malarials, and gold compounds can be 
continued during surgery. However, leflunomide, sulfasalazine, azathioprine, and 
cyclosporine A should be withdrawn due to the increased risk of infection associated with 
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their use. With regard to the new biological therapies, it should be borne in mind that they 
inhibit cytokines and modulate cells that participate in the physiological response against 
infections and in wound-healing. Until data from well-designed prospective studies become 
available, it therefore appears prudent to withdraw these drugs before surgery for a time 
interval based on their pharmacokinetics.     
5. Key points 
1. In patients with inflammatory arthropies requiring orthopedic surgery, good clinical 
and biological control of the disease must be obtained before the intervention; therefore, 
coordination between orthopedic surgeon and rheumatologist  is essential. 
2. We must know the biological and non-biological therapies received by our patients for 
their perioperative management, thereby reducing the risk of infection and surgical 
wound-healing complications. 
3. Methotrexate can be maintained during the perioperative period, but leflunomide, 
sulfasalazine, azathioprine, and cyclosporine A should be suspended, because available 
studies suggest their association with a higher infection  risk. 
4. T and B cells and cytokines (tumor necrosis factor-alpha, interleukin 6, and interleukin 1) 
are involved in anti-infection defense and surgical wound-healing and are modulated 
or blocked by biological therapies administered to patients with inflammatory 
arthropaties.  
5. There have been no clinical trials on surgical complications in patients with 
inflammatory arthropaties receiving biological therapies; therefore, recommendations 
are based on retrospective and animal studies.  
6. Retrospective studies suggest that infliximab and etanercept can be safely administered 
during the perioperative period to patients undergoing orthopedic surgery without 
increasing their risk of infection or wound-healing complications. 
7. Murine studies suggest that collagenization of the surgical wound is improved by the 
inhibition of tumor necrosis factor-alpha with etanercept. 
8. In patients under treatment with rituximab, it is recommendable to  program the 
surgery once the serum count of CD-19 B lymphocytes has normalized; however, if this 
is not possible, its administration should not be considered a contraindication for the 
surgery. 
9. Tocilizumab blocks IL-6, inducing the hepatic synthesis of C-reactive protein (CRP), 
which can mask the signs and symptoms of infectious post-surgical complications such 
as fever or elevated CRP. 
10. Given the absence of high-quality scientific evidence, we recommend suspending 
biological therapies before the surgery in accordance with their half-life and not 
reintroducing them until the surgical wound has healed.  
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